Therapeutic research efforts have focused on amyloid-β protein and tau aggregates, emphasizing the importance of an accurate postmortem neuropathologic diagnosis of Alzheimer’s disease to support antemortem biomarkers and clinical diagnoses [2,56]. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.